Drug Profile
Nalmefene - TaiwanJ Pharmaceuticals
Alternative Names: JKB-121; Nalmetrene - TaiwanJ PharmaceuticalsLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Jenken Biosciences
- Developer Duke University Medical Center
- Class Anti-inflammatories; Opioid analgesics
- Mechanism of Action Opioid receptor antagonists; Toll-like receptor 4 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Non-alcoholic steatohepatitis
Most Recent Events
- 27 Aug 2019 Discontinued - Phase-II for Non-alcoholic steatohepatitis in USA (PO)
- 11 Apr 2018 Efficacy and adverse events data from a phase II trial in Non-alcoholic steatohepatitis presented at the International Liver Congress (ILC-2018) (NCT02442687)
- 29 Sep 2015 TaiwanJ Pharmaceuticals has patents pending for nalmefene in USA and other countries